ERBB2 and breast neoplasm: On the subgroup analysis, locoregional treatment for primary breast tumor showed significant survival benefit in patients with luminal-like (Figure 1, P = 0.0001) and HER2-enriched (Figure 2, P = 0.0012) subtype.